TB-500 how to inject: reconstitution, sites, and technique

Last updated 2026-07-25

What is TB-500 and how is it different from thymosin beta-4?

TB-500 is the name used in the peptide research and doping-control world for a synthetic peptide built around an active fragment of thymosin beta-4 (Tβ4), the naturally occurring 43-amino-acid protein found throughout human tissue. They are related, not identical. Native Tβ4 is the full-length endogenous protein; TB-500 as sold online is usually a shorter synthetic construct, and some products marketed under that name are actually the N-terminal acetylated 17-23 fragment of Tβ4, which researchers synthesized and characterized specifically because of its suspected doping potential ^[1]. That distinction matters for anyone trying to read the literature. A study on thymosin beta-4 itself is not automatically a study on the injectable product people call TB-500. Analytical chemists doing doping control have spent over a decade building assays specifically to tell these molecules apart in blood, urine, and plasma ^[2][3], which tells you the industry itself treats them as separate analytes worth distinguishing, not interchangeable names for the same thing. If you want the fuller evidence picture before technique, the TB-500 hub page lays out what's actually been studied versus what's marketing.

How do you reconstitute TB-500 before injecting it?

Reconstitution follows the same basic peptide-handling logic used across the research supply chain: lyophilized (freeze-dried) peptide in a vial gets mixed with a liquid, usually bacteriostatic water, to bring it into solution before it can be drawn into a syringe. None of the cited studies in this pack describe a human clinical reconstitution protocol for TB-500, because none of them are human trials of the compound as a therapeutic. The reconstitution practices you see in the peptide community come from general handling conventions, not from a published clinical dosing paper. What is published is analytical work confirming TB-500 and its breakdown products can be measured precisely once in solution. A 2024 paper in the Journal of Chromatography B developed a method to simultaneously quantify TB-500 and its metabolites in both in-vitro experiments and in rats, using UHPLC-Q-Exactive Orbitrap MS/MS, and screened the fragments for wound-healing activity in vitro ^[4]. That's a real signal that the molecule and its breakdown products are pharmacologically active in a dish and in rodents. It is not a human dosing study, and it says nothing about how much to reconstitute with, what concentration to mix to, or how often to inject. Because there's no clinical protocol to cite, treat any specific reconstitution ratio or storage instruction you see online as a common practice, not a proven one. For handling and shelf-life specifics once mixed, see TB-500 storage and shelf life.

Subcutaneous or intramuscular: which injection method does the research use?

Across the analytical and toxicology literature, TB-500 (and thymosin beta-4 more broadly) is studied as an injectable peptide, and the two routes discussed in adjacent orthopaedic peptide literature are subcutaneous and intramuscular. A 2026 primer in The American Journal of Sports Medicine on injectable peptide therapy for orthopaedic and sports medicine physicians frames the broader category of peptide injectables used in this space, covering how these compounds are handled clinically as a class ^[5]. A companion 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics more broadly, including the applications, challenges, and open questions clinicians face with this drug class ^[6]. Neither paper hands you a TB-500-specific dosing chart, and that's the honest limit of the evidence right now. What the community practice has settled on, subcutaneous injection near the site of injury or in standard subcutaneous zones (abdomen, thigh), reflects general peptide-injection convention rather than a TB-500 clinical trial finding. If you're deciding where on the body to inject and why, that's covered in more detail at TB-500 injection sites.

What needle gauge and syringe size do people use?

Insulin syringes, typically 29 to 31 gauge with a 0.3 to 1 mL barrel, are the standard tool people use for small-volume subcutaneous peptide injections generally. This is a practical convention borrowed from insulin and other peptide self-injection practices (like BPC-157), not a finding from a TB-500-specific trial. A thinner gauge (31G) is less painful for frequent subcutaneous dosing but can be slower to draw viscous solutions. A slightly thicker gauge (29G) draws faster and is more forgiving if the reconstituted solution isn't perfectly clear, at the cost of a bit more discomfort at injection. Neither choice is supported by outcome data because no controlled trial has compared them for this compound. Sites: rotate. Repeated injection into the same one-inch patch of skin causes local irritation and, anecdotally, scar tissue buildup over weeks. That's basic injection hygiene, not a TB-500-specific finding.

How often and for how long do people inject TB-500?

There is no FDA-approved dosing schedule for TB-500, because there is no FDA-approved TB-500 product. Search Drugs@FDA and you won't find it listed ^[7]. Any frequency or cycle-length number you see quoted (daily, twice weekly, a 4-6 week loading phase followed by maintenance) comes from user-reported practice and vendor literature, not from a peer-reviewed human dosing trial. The 2026 Sports Medicine review on safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance groups TB-500 among the unapproved peptides circulating in sports and recovery contexts, evaluating what's known and not known about safety and efficacy across that category ^[8]. That paper is the closest thing to an authoritative statement on where TB-500 sits regulatorily and evidentially, and it puts it firmly in the unapproved category alongside other peptides physicians are now being asked about in clinic. If you want a structured look at cycle-length conventions and why people take breaks between courses, see TB-500 cycle length.

Is there any published human clinical trial on TB-500 injections?

No. Every citation available on TB-500 specifically is either analytical chemistry (methods to detect and quantify it in blood, urine, or plasma for doping control) or preclinical work in cells and rats. The 2024 Journal of Chromatography B paper tested wound-healing activity in vitro and dosed rats, not humans ^[4]. The doping-control literature spans equine plasma and urine studies ^[9][10], human anti-doping detection method development ^[2][3], and in-vitro metabolic modeling using liver and kidney microsomes, S9 fractions, and blood serum ^{[11][12][13][14]}, none of which are efficacy trials in injured human patients. That's worth sitting with for a second: an entire analytical-chemistry subfield has grown up around detecting TB-500 in doping samples, while zero registered human clinical trials have tested whether injecting it heals anything in people. The interest from anti-doping labs is itself indirect evidence that it's being used in populations (mostly athletes and horses) despite the absence of human efficacy data.

Is TB-500 legal, and is it banned in sport?

TB-500 and thymosin beta-4 fall under WADA's prohibited list as growth factors and related substances, which matters directly if you compete under a testing authority. Anti-doping labs have built specific LC-MS and LC-MS/MS methods to catch it in equine urine and plasma ^[9][10] and in human doping samples generally ^[2][3], and adsorption studies have been done specifically to understand how TB-500 behaves during sample prep so labs don't miss it due to surface binding losses ^[15]. On the regulatory side in the US, no thymosin beta-4 fragment or TB-500 construct appears on the FDA's 503A bulk drug substances list ^[16] or the 503B bulks list ^[17], the two lists that define what compounding pharmacies can legally use to make patient-specific preparations. FDA's compounding statute, 21 U.S.C. 353a, sets the framework compounding pharmacies operate under ^[18], and FDA's own bulk drug substances page for 503A explains how substances get nominated and reviewed for that list ^[16]. TB-500 nowhere appears as an approved bulk substance, which is a meaningful gap if you're evaluating claims that a product is "pharmacy compounded." This is why you'll never see TB-500 sold as its own standalone injectable SKU from a legitimate source. What you'll actually find dispensed is a combined BPC-157/TB-500 blend, sourced through a provider-reviewed pathway rather than as an isolated TB-500 vial.

How is TB-500 actually sourced and dispensed, if not as a standalone product?

This is the part most vendor sites gloss over. Because TB-500 isn't on FDA's approved bulk drug substance lists for compounding ^[16][17], and because there's no FDA-approved drug product under that name ^[7], a legitimate, provider-involved pathway won't offer it as an isolated product. What's actually available through reviewed channels is a BPC-157/TB-500 blend, dispensed together, not TB-500 alone. TB-500 Co works with a fulfilling pharmacy partner on that reviewed pathway; the point isn't to push a purchase, it's to be straight about what actually exists on the market versus what gets implied by "buy TB-500" landing pages selling a lone vial. If you're comparing sourcing options, TB-500 for sale walks through what a provider-reviewed route looks like versus a straight research-chemical purchase, and the tradeoffs of each. One more distinction worth knowing before you shop: TB-500 as sold is not the same molecule tested in most of the aging and regenerative literature on native thymosin beta-4, including recent work on therapeutic peptides in gerontology covering mechanisms relevant to healthy aging ^[19]. That paper is about endogenous Tβ4 biology broadly, not a clinical trial of the synthetic injectable product.

What about the BPC-157 pairing? Does it change how you inject?

People running BPC-157 and TB-500 together generally inject them as separate subcutaneous shots or, more commonly given the blend format, from the same reconstituted vial when dispensed as a combination product. Since there's no standalone TB-500 SKU, this isn't really an optional pairing decision on the reviewed pathway, it's how the product is formulated to begin with. Mechanistically, the two peptides are proposed to work on different angles of tissue repair (BPC-157 on gut and tendon-adjacent angiogenesis pathways, Tβ4-derived TB-500 on actin regulation and cell migration), but that mechanistic story again rests almost entirely on preclinical and in-vitro work, not controlled human trials of the combination. If you want the comparison laid out side by side against the native peptide, see TB4 peptide vs TB500.

What mistakes do people make when injecting TB-500?

The most common ones aren't exotic. Injecting into the same spot repeatedly without rotating causes local tissue irritation. Drawing from a vial that's been reconstituted and left at room temperature for days risks degradation and contamination, since peptides in solution are much less stable than lyophilized powder. Reusing needles introduces infection risk with no upside. A less obvious mistake: assuming a frequency or dose because a forum post said so. None of those numbers trace back to a human clinical trial. The honest baseline is that dosing conventions here are crowd-sourced practice, not medicine, and the injectable peptide primer literature aimed at physicians is explicit that this category needs more rigorous study before dosing can be standardized ^[5][6][8].

How do labs even detect and confirm TB-500 in a sample?

This is a genuinely well-developed corner of analytical chemistry, even though the clinical-use side is thin. Methods include direct urine injection combined with liquid chromatography and ion mobility mass spectrometry for peptides under 2 kDa ^[14], solid-phase extraction of small bioactive peptides from human urine using cartridges and 96-well microelution plates ^[15], and multi-peptide panels detecting seven bioactive peptides at once in horse plasma ^[10]. Reviews of the field cover both current detection status and where the methods are headed next ^[2][3]. The reason this matters beyond doping labs: it tells you TB-500 is a real, chemically stable, detectable molecule with a known mass and fragmentation pattern, not a vague marketing term. That's useful context when you're trying to separate legitimate analytical science about the molecule from unsupported healing claims about injecting it.

Frequently asked questions

Can you inject TB-500 by itself, or does it always come with BPC-157?

Through reviewed, provider-involved sourcing, TB-500 is dispensed as a combined BPC-157/TB-500 blend, not as a standalone vial. There's no legitimate standalone TB-500 SKU on that pathway. If a seller offers pure TB-500 alone with no provider review, that's a red flag worth scrutinizing given TB-500 isn't on FDA's approved compounding bulk lists ^[16][17].

Is TB-500 the same thing as thymosin beta-4?

No. Thymosin beta-4 (Tβ4) is the naturally occurring 43-amino-acid protein. TB-500 is a synthetic construct built around an active fragment of it, and some products marketed under that name are specifically the N-terminal acetylated 17-23 fragment ^[1]. They're related but chemically distinct, and studies on one don't automatically apply to the other.

What needle size is used for TB-500 injections?

Practice convention uses insulin syringes, 29 to 31 gauge, similar to what's used for BPC-157 and other small-volume peptide self-injections. This isn't from a TB-500-specific clinical trial, it's borrowed from general peptide-injection practice, so treat it as common usage rather than a validated protocol.

Subcutaneous or intramuscular: which is better for TB-500?

Both routes appear in general peptide-injection practice, and orthopaedic peptide primers discuss the category broadly ^[5][6], but no published trial compares subcutaneous versus intramuscular TB-500 injection for outcomes in humans. Subcutaneous near the injury site is the more common community practice, largely for ease of self-injection rather than proven superiority.

How long does reconstituted TB-500 last once mixed?

There's no published clinical stability study specific to TB-500 in solution. General peptide handling convention says use reconstituted solution within days to a couple weeks when refrigerated, but this is common practice, not a tested shelf-life figure. See storage and shelf-life guidance for the fuller breakdown.

Is TB-500 banned for athletes?

Yes. TB-500 and thymosin beta-4-related substances fall under WADA's prohibited list, and anti-doping labs have built specific detection methods for it in both human and equine samples ^[2][9][10]. Any competing athlete under a testing authority should treat it as a banned substance, not a gray area.

Has TB-500 been tested in human clinical trials?

No registered human clinical trial of TB-500 for injury repair currently exists in the cited literature. Available data are preclinical: in-vitro wound-healing screens and rat dosing ^[4], plus analytical chemistry for detection in blood, urine, and plasma ^[9][10]. Human efficacy and dosing remain unestablished as of this writing.

Where on the body do people inject TB-500?

Common practice uses standard subcutaneous zones (abdomen, thigh) or injection near the site of a specific injury. This reflects general peptide self-injection convention, not a TB-500-specific trial finding. See the injection-sites guide for site-by-site detail and rotation practice.

Why isn't TB-500 available as an FDA-approved drug?

Searching Drugs@FDA turns up no approved product under that name ^[7], and TB-500 doesn't appear on FDA's 503A or 503B bulk drug substance lists that govern what compounding pharmacies may legally use ^[16][17]. That's why it's only available through research-chemical channels or as part of a provider-reviewed compounded blend.

What's the difference between TB-500 research and BPC-157 research?

Both are peptides studied mostly in preclinical, in-vitro, and animal settings for tissue repair, but they're proposed to act through different mechanisms, TB-500 tied to actin regulation and cell migration derived from thymosin beta-4 biology, BPC-157 tied to angiogenesis-related pathways. Neither has a completed human efficacy trial establishing dosing or outcomes.

How do anti-doping labs actually detect TB-500 in a sample?

Methods include LC-MS/MS panels for multiple bioactive peptides in plasma ^[10], solid-phase extraction from urine using microelution plates ^[15], and direct urine injection with ion mobility mass spectrometry for peptides under 2 kDa ^[14]. Adsorption studies also address how TB-500 behaves during sample prep to avoid detection losses ^[13].

Does TB-500 cycle length matter for injection frequency?

There's no clinical trial establishing an optimal cycle length, so frequency conventions (daily or several times weekly for a loading period, then tapering) come entirely from user practice, not controlled data. See the cycle-length page for how those informal protocols are typically structured and why people build in breaks.

Sources

1. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500 (Drug Testing and Analysis, 2012): TB-500 as sold is characterized as the N-terminal acetylated 17-23 fragment of thymosin beta-4, synthesized specifically due to suspected doping potential, distinguishing it from full-length native Tβ4.
2. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls (Journal of Pharmaceutical and Biomedical Analysis, 2014): Anti-doping labs have developed specific analytical approaches to detect emerging non-approved therapeutics, including TB-500, in human doping samples.
3. Detecting peptidic drugs, drug candidates and analogs in sports doping (Expert Review of Proteomics, 2014): Reviews current status and future directions for detecting peptidic drugs and analogs like TB-500 in sports doping control.
4. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats (Journal of Chromatography B, 2024): A UHPLC-Q-Exactive Orbitrap MS/MS method quantified TB-500 and its metabolites in vitro and in rats, and screened fragments for wound-healing activity in vitro.
5. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (American Journal of Sports Medicine, 2026): Provides physician-facing guidance on the injectable peptide therapy category used in orthopaedic and sports medicine settings.
6. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026): Reviews applications, challenges, and future directions for therapeutic peptides used in orthopaedics as a drug class.
7. Drugs@FDA, FDA-approved drug products database: No TB-500 or thymosin beta-4 injectable product appears as an FDA-approved drug in the Drugs@FDA database.
8. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026): Groups TB-500 among unapproved peptide therapies used for musculoskeletal injuries and athletic performance, evaluating safety and efficacy evidence gaps.
9. Doping control analysis of TB-500 in equine urine and plasma by LC-MS (Journal of Chromatography A, 2012): Developed a liquid chromatography-mass spectrometry method to detect TB-500 specifically in equine urine and plasma for doping control.
10. Doping control analysis of seven bioactive peptides in horse plasma by LC-MS (Analytical and Bioanalytical Chemistry, 2013): Developed an LC-MS method detecting seven bioactive peptides, including TB-500-related compounds, simultaneously in horse plasma.
11. In vitro models for metabolic studies of small peptide hormones in sport drug testing (Journal of Peptide Science, 2015): Reviews in-vitro metabolic models used to study small peptide hormones, relevant to how TB-500 is metabolically characterized for testing.
12. Comparison of in vitro model systems of the metabolism of synthetic doping peptides (Journal of Proteomics, 2016): Compared proteolytic enzymes, human blood serum, liver and kidney microsomes, and liver S9 fraction as in-vitro models for synthetic doping peptide metabolism.
13. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5 (Analytical Biochemistry, 2017): Studied how TB-500 and related doping-relevant peptides adsorb to surfaces during sample handling, affecting detection accuracy.
14. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, LC, and ion mobility MS (Journal of Separation Science, 2016): Developed a direct urine injection method with ion mobility mass spectrometry to screen for small peptides under 2 kDa.
15. Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine (Drug Testing and Analysis, 2016): Developed solid-phase extraction methods using cartridges and microelution plates to isolate small bioactive peptides from human urine for doping analysis.
16. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: Defines and lists the bulk drug substances FDA has reviewed and permits for use in 503A pharmacy compounding; TB-500 does not appear on this list.
17. 21 CFR 216.24, the 503B Bulks List: Establishes the bulk drug substances list for 503B outsourcing facility compounding; TB-500 is not included on this regulatory list.
18. 21 U.S.C. 353a, pharmacy compounding statute: Sets the federal statutory framework under which pharmacy compounding of drug products, including peptide blends, is legally permitted.
19. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026): Reviews mechanisms and applications of therapeutic peptides, including thymosin beta-4 biology, relevant to healthy aging research.